4174.TWO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 08:30):

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally...

Stats
Dzisiejszy wolumen	195 003
Średni wolumen	413 867
Kapitalizacja rynkowa	14.10B
EPS	TWD0 ( 2024-03-13 )
Następna data zysków	( TWD0 ) 2024-05-10
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-13.46
ATR14	TWD0.0970 (0.16%)

Wolumen Korelacja

Długi: -0.29 (neutral)

Krótki: 0.52 (weak)

Signal:(52.548) Neutral

OBI Pharma, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

OBI Pharma, Inc. Korelacja - Waluta/Towar

-0.36
( neutral )

-0.52
( weak negative )

0.00
( neutral )

0.63
( weak )

0.57
( weak )

OBI Pharma, Inc. Finanse

Annual	2023
Przychody:	TWD41.55M
Zysk brutto:	TWD-73.50M (-176.89 %)
EPS:	TWD-5.53

FY	2023
Przychody:	TWD41.55M
Zysk brutto:	TWD-73.50M (-176.89 %)
EPS:	TWD-5.53

FY	2022
Przychody:	TWD4.71M
Zysk brutto:	TWD-40.14M (-852.13 %)
EPS:	TWD-8.55

FY	2021
Przychody:	TWD18.77M
Zysk brutto:	TWD-25.59M (-136.32 %)
EPS:	TWD-7.71

Financial Reports:

No articles found.

OBI Pharma, Inc.

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898 and OBI-998 drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.

Aktualne aktualizacje dla OBI Pharma, Inc. [4174.TWO]

Upcoming Earnings Alert